Mannkind (MNKD) Non-Current Deffered Revenue (2017 - 2026)
Mannkind (MNKD) reported Non-Current Deffered Revenue of $38.9 million for Q1 2026, down 17.85% year-over-year from $47.4 million in Q1 2025, and down 2.68% on a QoQ basis from $40.0 million in Q4 2025.
Mannkind (MNKD) has 10 years of Non-Current Deffered Revenue data on file, last reported at $38.9 million in Q1 2026.
- Quarterly Non-Current Deffered Revenue fell 17.85% year-over-year to $38.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.9 million (down 17.85% YoY) and the FY2025 annual result came in at $40.0 million, down 21.86% from the prior year.
- Non-Current Deffered Revenue declined to $38.9 million in Q1 2026 per MNKD's latest filing, from $40.0 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $69.8 million in Q4 2023 and bottomed at $1.2 million in Q1 2023.
- The 5-year median for Non-Current Deffered Revenue is $47.4 million (2025), against an average of $46.8 million.
- The widest annual swing landed in 2023, when Non-Current Deffered Revenue slumped 95.41%; it then surged 5545.08% in 2024.
- Tracing MNKD's Non-Current Deffered Revenue over 5 years: stood at $37.7 million in 2022, then surged by 85.21% to $69.8 million in 2023, then decreased by 26.7% to $51.2 million in 2024, then dropped by 21.86% to $40.0 million in 2025, then decreased by 2.68% to $38.9 million in 2026.
- Per Business Quant, the three latest MNKD Non-Current Deffered Revenue figures stand at $38.9 million (Q1 2026), $40.0 million (Q4 2025), and $48.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn | 38.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.91 Mn |
| Dec 31, 2025 | 39.98 Mn |
| Sep 30, 2025 | 48.19 Mn |
| Jun 30, 2025 | 45.47 Mn |
| Mar 31, 2025 | 47.36 Mn |
| Dec 31, 2024 | 51.16 Mn |
| Sep 30, 2024 | 65.15 Mn |
| Jun 30, 2024 | 66.12 Mn |
| Mar 31, 2024 | 67.74 Mn |
| Dec 31, 2023 | 69.79 Mn |
| Sep 30, 2023 | 69.47 Mn |
| Jun 30, 2023 | 60.25 Mn |
| Mar 31, 2023 | 1.20 Mn |
| Dec 31, 2022 | 37.68 Mn |
| Sep 30, 2022 | 32.00 Mn |
| Jun 30, 2022 | 29.76 Mn |
| Mar 31, 2022 | 26.12 Mn |
| Dec 31, 2021 | 19.54 Mn |
| Sep 30, 2021 | 1.55 Mn |
| Jun 30, 2021 | 1.59 Mn |
| Mar 31, 2021 | 1.63 Mn |
| Dec 31, 2020 | 1.66 Mn |
| Sep 30, 2020 | 1.70 Mn |
| Jun 30, 2020 | 4.86 Mn |
| Mar 31, 2020 | 1.77 Mn |
| Dec 31, 2019 | 8.34 Mn |
| Sep 30, 2019 | 2.63 Mn |
| Jun 30, 2019 | 8.40 Mn |
| Mar 31, 2019 | 15.87 Mn |
| Dec 31, 2018 | 10.68 Mn |
| Dec 31, 2017 | 500,000.00 |